Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes
- 30 April 2005
- journal article
- Published by Elsevier BV in Prostaglandins, Leukotrienes & Essential Fatty Acids
- Vol. 72 (4), 267-272
- https://doi.org/10.1016/j.plefa.2004.12.003
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancerEndocrine-Related Cancer, 2004
- Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancerProstaglandins, Leukotrienes & Essential Fatty Acids, 2003
- SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactionsOncogene, 2003
- Expression of peroxisome‐proliferator activated receptor‐gamma (PPARγ) and the PPARγ co‐activator, PGC‐1, in human breast cancer correlates with clinical outcomesInternational Journal of Cancer, 2003
- Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progressionCancer, 2003
- Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cellsOncogene, 2002
- ANALYSIS OF THE GENE EXPRESSION OF SPARC AND ITS PROGNOSTIC VALUE FOR BLADDER CANCERJournal of Urology, 2001
- SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer CellsThe American Journal of Pathology, 2001
- Calcium signals in prostate cancer cells: specific activation by bone-matrix proteinsCell Calcium, 2000
- Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: Sequence, expression, and localization of the gene to chromosome 5q31-q33Genomics, 1988